Technical Analysis for TRVI - Trevi Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Earnings Movers | Other | -8.97% | |
| BB Squeeze Ended | Range Expansion | -8.97% | |
| Fell Below 50 DMA | Bearish | -10.20% | |
| Bollinger Band Squeeze | Range Contraction | -10.20% | |
| BB Squeeze + Upper Band Touch | Range Contraction | -10.20% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 12 hours ago |
| 20 DMA Resistance | about 15 hours ago |
| 20 DMA Support | about 16 hours ago |
| Gapped Down (Full) | about 17 hours ago |
| Down 5% | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Trevi Therapeutics, Inc. Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Organic Compounds Chemical Compounds Opioids Idiopathic Pulmonary Fibrosis Analgesics Ethers Pulmonary Fibrosis Nervous System Morphinans Physiology Cough Phenols Opioid Receptors Parkinson’s Disease Pruritus Dyskinesia Peripheral Nervous System Prurigo Prurigo Nodularis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.0 |
| 52 Week Low | 0.9712 |
| Average Volume | 249,988 |
| 200-Day Moving Average | 2.10 |
| 50-Day Moving Average | 3.02 |
| 20-Day Moving Average | 2.82 |
| 10-Day Moving Average | 2.86 |
| Average True Range | 0.25 |
| RSI (14) | 41.86 |
| ADX | 15.01 |
| +DI | 20.12 |
| -DI | 31.30 |
| Chandelier Exit (Long, 3 ATRs) | 2.45 |
| Chandelier Exit (Short, 3 ATRs) | 3.10 |
| Upper Bollinger Bands | 3.11 |
| Lower Bollinger Band | 2.54 |
| Percent B (%b) | 0.18 |
| BandWidth | 20.45 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.15 | ||||
| Resistance 3 (R3) | 3.17 | 3.01 | 3.07 | ||
| Resistance 2 (R2) | 3.01 | 2.88 | 3.00 | 3.04 | |
| Resistance 1 (R1) | 2.82 | 2.80 | 2.92 | 2.81 | 3.01 |
| Pivot Point | 2.67 | 2.67 | 2.71 | 2.66 | 2.67 |
| Support 1 (S1) | 2.48 | 2.54 | 2.57 | 2.47 | 2.27 |
| Support 2 (S2) | 2.32 | 2.45 | 2.32 | 2.24 | |
| Support 3 (S3) | 2.14 | 2.32 | 2.21 | ||
| Support 4 (S4) | 2.13 |
